-
2026-01-16
GenSci Unveils 7 Innovative Pipeline at JPM 2026Learn More
-
2025-12-23
GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global CommercializationLearn More
-
2025-12-16
GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW InvestmentsLearn More
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More
-
2025-07-04
Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 MonthsLearn More
-
2025-06-18
NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral SuspensionLearn More
-
2024-07-23
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection AcceptedThis product will potentially enhance convenience and patient compliance
Learn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia® in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More